VistaGen Therapeutics (VTGN) Expected to Announce Quarterly Earnings on Thursday

VistaGen Therapeutics (NASDAQ:VTGN) is anticipated to post its Q2 2027 results before the market opens on Thursday, November 12th. Analysts expect VistaGen Therapeutics to post earnings of ($0.3750) per share and revenue of $0.50 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2027 earnings overview page for the latest details on the call scheduled for Thursday, November 19, 2026 at 5:00 PM ET.

VistaGen Therapeutics (NASDAQ:VTGN) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.06. VistaGen Therapeutics had a negative return on equity of 152.59% and a negative net margin of 2,702.64%. The company had revenue of $1.48 million during the quarter, compared to the consensus estimate of $0.50 million. On average, analysts expect VistaGen Therapeutics to post ($1.45) EPS for the current fiscal year and ($1.54) EPS for the next fiscal year.

VistaGen Therapeutics Stock Performance

Shares of VistaGen Therapeutics stock opened at $0.18 on Tuesday. VistaGen Therapeutics has a 52-week low of $0.16 and a 52-week high of $5.14. The stock’s 50-day simple moving average is $0.23 and its 200 day simple moving average is $0.43. The stock has a market capitalization of $8.18 million, a P/E ratio of -0.11 and a beta of 0.49.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of VistaGen Therapeutics in a research report on Monday, August 31st. Four equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Reduce” and an average target price of $0.95.

About VistaGen Therapeutics

Vistagen Therapeutics, Inc (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company developing therapies for central nervous system and neuropsychiatric disorders. The company focuses on intranasal treatments designed to act rapidly and address conditions for which patients may need alternatives to conventional systemic medicines.

Vistagen’s lead investigational product is fasedienol, also known as PH94B, a nasal spray being studied as a potential treatment for social anxiety disorder.